Glioblastoma is the most common and the most aggressive type of brain cancer. Aberrations of the RTK/RAS/PI3K-, p53-, and RB cell signaling pathways were recognized as a core requirement for pathogenesis of glioblastoma. The p53 tumor suppressor functions as a transcription factor transactivating expression of its target genes in response to various stress stimuli. We determined the p53 status in 36 samples of glioblastoma by functional analyses FASAY and split assay. Seventeen p53 mutations were detected and further analyzed by cDNA and gDNA sequencing in 17 patients (47.2 %). Fifteen (88.2 %) of the mutations were missense mutations causing amino acid substitutions, seven of them exhibited temperature-sensitivity. Two mutations were determined as short deletions, one of them causing formation of premature termination codon in position 247. Fluorescent in situ hybridization revealed the loss of the p53-specific 17p13.3 locus in four of 33 analyzed samples (12 %). In 12 out of 30 samples (40 %), the p53 protein accumulation was shown by immunoblotting. There was high (80 %) concordance between the presence of the clonal p53 mutation and the p53 protein accumulation.

Department of Pathology University Hospital Brno Jihlavska 20 62500 Brno Czech Republic

Zobrazit více v PubMed

Mol Carcinog. 1997 Mar;18(3):171-6 PubMed

Cancer Res. 1992 May 15;52(10):2987-90 PubMed

Int J Oncol. 2011 Dec;39(6):1413-20 PubMed

Nature. 1992 Feb 27;355(6363):846-7 PubMed

FEBS Lett. 1997 Dec 22;420(1):25-7 PubMed

Tumour Biol. 2001 Mar-Apr;22(2):59-66 PubMed

Hum Mutat. 2007 Jun;28(6):622-9 PubMed

Oncogene. 1997 Jan 16;14(2):163-9 PubMed

Nature. 1997 May 15;387(6630):296-9 PubMed

Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):3963-7 PubMed

Nat Genet. 1993 Oct;5(2):124-9 PubMed

Cancer Res. 1998 May 1;58(9):1793-7 PubMed

Cancer Res. 2005 May 15;65(10):4051-8 PubMed

J Neurooncol. 2001 May;52(3):263-72 PubMed

Cancer Res. 2004 Oct 1;64(19):6892-9 PubMed

Brain Tumor Pathol. 2010 Oct;27(2):95-101 PubMed

Science. 2008 Sep 26;321(5897):1807-12 PubMed

Oncogene. 1998 May 14;16(19):2527-39 PubMed

J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 PubMed

Curr Opin Oncol. 2011 Jan;23(1):88-92 PubMed

Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):228-33 PubMed

Oncogene. 2008 Feb 21;27(9):1243-52 PubMed

Int J Oncol. 2003 Jul;23(1):121-31 PubMed

Cancer Res. 1988 Oct 1;48(19):5546-51 PubMed

Oncol Rep. 2004 Apr;11(4):923-9 PubMed

Oncogene. 2005 Apr 18;24(17):2899-908 PubMed

Carcinogenesis. 2007 Feb;28(2):289-98 PubMed

Oncogene. 2001 Jun 14;20(27):3573-9 PubMed

J Neurooncol. 2000 Sep;49(3):197-203 PubMed

J Neuropathol Exp Neurol. 2002 Apr;61(4):321-8 PubMed

Proc Natl Acad Sci U S A. 1989 Apr;86(8):2858-62 PubMed

J Biol Chem. 2004 Jan 2;279(1):348-55 PubMed

Genes Dev. 1993 Jul;7(7A):1126-32 PubMed

Nucleic Acids Res. 1992 Apr 11;20(7):1539-45 PubMed

Cancer Res. 1994 Feb 1;54(3):649-52 PubMed

Clin Cancer Res. 1997 Apr;3(4):523-30 PubMed

J Clin Pathol. 2010 Aug;63(8):687-91 PubMed

Clin Cancer Res. 2002 May;8(5):1117-24 PubMed

J Pathol. 2005 Nov;207(3):251-9 PubMed

Nature. 2008 Oct 23;455(7216):1061-8 PubMed

Oncol Rep. 2002 Jul-Aug;9(4):703-7 PubMed

Cancer Res. 1988 Jan 15;48(2):405-11 PubMed

Jpn J Cancer Res. 2000 Feb;91(2):181-9 PubMed

Neoplasma. 1999;46(6):384-9 PubMed

J Neurooncol. 2000 Jun;48(2):89-94 PubMed

Cancer Res. 2002 May 15;62(10):2897-905 PubMed

Cell. 2004 Jan 23;116(2):235-46 PubMed